NEW YORK (GenomeWeb) – N-of-One said this week that it has been selected by CeGaT to provide interpret data from its next-generation sequencing-based oncology tests.

Under the terms of the agreement, N-of-One will analyze data from CeGaT's NGS panel which tests for more than 550 cancer genes. The company's interpretation results will include biological and clinical information about mutations found in the tumor as well as access to potential therapeutic strategies and clinical trials.

Financial and other terms of the deal were not disclosed

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: GWAS links gene to noise-induced hearing loss in mice, population genetics of malaria parasites, and more.

Nautilus' Alexandra Ossola examines how Tay-Sachs disease jump-started the genetic disease testing field.

FASEB says guidelines proposed by the NIH to bolster research reproducibility are premature and don't take the full range of scientific studies into consideration.

Liquid biopsies and DNA tests may be able to tell physicians whether a cancer patient is relapsing, the New York Times reports.

May
28
Sponsored by
PerkinElmer

This online seminar will demonstrate how RNA-seq analysis in a model organism can provide insights into human disease.